From Invention to Scale
TAP Sciences operates across the full supply chain from invention to innovation, originating, evaluating, and advancing programs within and across deep tech domains. Research and development form a continuous relationship: more rigorous research produces more tractable development, and the demands of development, held in productive tension rather than imposed as a constraint, make research more precise. TAP is built to sustain that relationship across an operating platform.
Science at the Table
The TAP team is configured as a distributed network: scientific, technical, capital, and operating expertise connected by shared methodology and human-machine collaboration, with the structure designed to form connections across disciplines and institutions as specific problems require. In most deep technology endeavors, the distance between a scientific insight and a capital decision runs through multiple intermediaries and sequential handoffs. TAP collapses that distance: the disciplines that usually operate in sequence work from the same evidence, in the same structure, at the same time. The non-technical barriers to progress in these sectors have historically been among the largest sources of friction and perceived capital intensity. The science accounts for only part of the challenge. The larger share of what looks like capital intensity is an artifact of how the work has been organized, financed, and governed. TAP is designed around the observation that better organization produces better science, and better science compounds. The platform contributes across the full development continuum, wherever cross-domain intelligence can improve a decision or extend the reach of a program.
Deep technology requires patient capital and specialized technical judgment exercised continuously over a long time horizon. TAP is built around this reality, combining the capital, the operating capability, and the domain expertise in a single structure designed to compound value over time. The evaluation posture is uncertainty-native: uncertainty is not a condition to be avoided but one to be characterized precisely enough to act deliberately. The transition from uncertainty to characterized risk unfolds continuously: evidence gathering, calibration, and deliberate positioning at each stage of a program's development.
The structural gap between a scientific discovery and its commercial application is a coordination problem. Organizational, financial, and logistical systems determine what gets worked on before the first hypothesis is formed, and what gets lost before it reaches the world. TAP operates across the full length of that supply chain, providing the institutional capability to move intellectual property from origination through commercial scale. In most research environments, a non-consensus position carries reputational exposure that exceeds its financial risk. TAP operates across the full range, including the positions that institutional constraints structurally foreclose.
The most persistent source of value destruction in deep technology is not bad science. It is premature confidence: capital committed to a resolved position before the highest-uncertainty questions have been answered. TAP's evaluation discipline is designed to work the other way. Uncertainty is characterized before capital moves, and the assessment updates continuously as evidence accumulates. The posture is prospective as well as protective: when evidence warrants, capital can move with conviction. Each stage of development is structured to answer the highest-uncertainty questions at the lowest possible cost. Risk is taken deliberately, at the right stage and at the right price.
The evaluation function recalibrates and compounds with every program cycle. Each new domain increases the frequency and quality of cross-domain interactions; each resolved program adds to the platform's pattern recognition. When three or more domains are engaged simultaneously within a single institutional structure, their combinations produce outputs that no bilateral pairing could generate alone. This is hypersynthesis: a qualitatively distinct category of insight that emerges from the concurrent engagement of domains held at genuine depth. Deep understanding of each domain is the departure point for the synthesis, not a casualty of it. A biology program benefits from what the platform knows about computational methods and materials behavior. A materials program draws on what the platform has learned about manufacturing constraints and biological environments. Programs entering the platform today benefit from everything the platform has learned. Programs entering in five years will benefit from more.
How a platform is organized, financed, and structured materially shapes what gets worked on and over what time horizon. The fields TAP operates in require decision-making across horizons that most organizational structures are not built to sustain: a duration mismatch that systematically underweights patient capital, and a companion incentive mismatch that rewards activity over accuracy. TAP resolves both as a structural requirement of the operating model. The incentive structure is designed so that wealth creation for the founding team and for investors is the same event, across the same time horizon.
TAP brings together dedicated teams and genuine domain expertise across multiple areas of deep tech, with partnerships that span a range of institutions and disciplines, from established relationships to early-stage collaborations. The connections that reach across these domains are the platform's core mechanism: a distributed intelligence network in which each addition opens simultaneous interactions across all existing areas. The boundaries between domains are maintained where they carry structural weight and made permeable where they generate cross-domain value. The value of the network grows non-linearly with each addition. Programs are selected for their scientific merit and their position in the network; in some cases they are actively structured to fill identified gaps.
Life Sciences applies TAP's evaluation discipline across therapeutic modalities, treating structural constraints in the field as design requirements for a better system rather than accepted features of it. Discovery at the frontier of biology is a data sparsity problem: the scarce resource is expert judgment, applied where signals are ambiguous and data incomplete. Experienced researchers set the hypotheses, interpret the signals, and direct resources where it matters most; AI and high-performance computing compress the search and extend each scientist's reach.
AI considered as a field remains early, particularly in scientific computing, where frontier problems are data-sparse and mechanisms are incompletely understood. Progress at this frontier requires high-performance computing infrastructure, hardware-aware architectures, models that reason abductively rather than interpolate within known distributions, and calibrated handling of heterogeneous scientific data. The hardware and materials work across TAP's other domains is the substrate these AI systems are built to run on and improve.
Semiconductors, advanced materials, quantum computing, photonics, and robotics and engineering systems are the enabling layers that determine what is computationally and physically possible. Their combinations produce outcomes no single field reaches alone: materials science informs semiconductor architecture, quantum algorithms require high-performance computing to develop and run, and robotics closes the loop from design to physical deployment.
When a frontier technology becomes legible enough to price, constrained demand crowds in simultaneously, re-rating prices in ways that often exceed what the underlying technical or risk event alone would justify. TAP establishes positions before that moment, at a basis set by evidence. The purchasing power of each committed dollar compounds: infrastructure built over years makes every subsequent dollar more productive, at declining marginal cost. Value accrues on multiple surfaces, from incremental program milestones through fundamental technology unlocks, opening new eligibility for financial buyers whose mandates have historically excluded this part of the supply chain. Structural capability, organizational design, and evaluation discipline are becoming the price of entry in research-dependent sectors. That position is available now, before the category is universally understood.
Structured to resolve the duration mismatch between asset owners and research-dependent sectors. Programs advance when evidence warrants it; positions return capital across nested time horizons, calibrated to stage of origination and technical demand. Paused programs preserve full option value. Capital recycles from commercialization events back into the next generation of programs.
Portfolio companies formed through the platform retain access to the network's evaluation infrastructure after formation. Commercial agility and coordination intelligence reinforce each other.
Special Assistant to the President, Biological Threats • Managing Director/Partner, BCG, PwC • Operation Warp Speed architect
Corporate and Technology Strategy • Entrepreneur, Co-Founder ValueAI Institute • Investor, Venture Partner
Senior Pharma Leadership • AI-driven Drug Discovery, Portfolio • Platform Technology and Science, GSK
Machine Learning, Deep Learning • AI Researcher/Instructor, Berkeley, NASA • Founder, Silicon Valley Bank AI Lab
Head of Operations, SaponiQx • Novavax Vaccine Lead, US Government Operation Warp Speed • Technology Selection and Clinical Evaluation, Department of Defense
Physician Executive & Software Engineer • Chief Medical Officer, United Healthcare, VA • Faculty, Harvard Medical School • Health Tech Turnaround Leader
DNA Encoded Libraries • Informatics & Molecular Biology, Dice Therapeutics
Management Systems • High Performance Organization • Senior Lecturer, MIT Sloan
Life Sciences Strategy & Business Operations • Supply Chain, Project Management • Boston Consulting Group
Senior Pharma Leadership • Collaborative Drug Discovery, InnoCentive • R&D Executive, Eli Lilly
Professor of Neurobiology & Behavior, UC Irvine • Director, UCI Brain Initiative • Co-Founder, Augnition Labs & Enthorin Therapeutics • Memory, neuroimaging & cognitive decline • PhD, UC Irvine
Professor and Head, Department of Neuroscience, University of Arizona • Member, BIO5 Institute • Director, Cognitive Aging and Neural Dynamics Lab • Cognitive aging, neurophysiology & circuit mechanisms, neuro-metabolism & cognitive decline • PhD, University of Arizona
Principal Scientist, O'Donnell Data Science & Research Computing Institute, SMU • HPC Applications Scientist, SMU • Adjunct Professor of Data Science, SMU • Computational Chemistry & Molecular Dynamics
Founder, RoutineHub • Sr TPM, WhatsApp (Meta) • Sr TPM, Amazon Alexa AI, launched first web-scale voice search engine • USC MBA
Founder, Ember Agentic Labs • Analytics & Data Science Engineering Manager, Google Cloud • Component Design Engineer, Intel • Berkeley MIDS
Kester & Byrnes Professor, Columbia Business School • Vice Dean of Research, CBS • ESG, Valuation & Corporate Governance • Schaefer Chair of Accounting, Emory University
Co-Founder & Managing Partner, Orient Growth Ventures • Co-Founder, Monitor Capital Investments & Monitor Capital Partners • LP Advisory Board, B Capital Group • Kellogg School of Management
Founder, Impact Evaluation Lab • Senior Founding Partner & Chief Risk Officer, Atlas Impact Partners • Senior Portfolio Manager, Equity Strategies, AllianceBernstein • Managing Director & Director of Research, Nomura Securities International • Executive Director, Head of Global Macro Research, Morgan Stanley
Head of AI, RealAvatar (Andrew Ng's AI Fund) • ML Science Manager, Amazon • AI Researcher, Megagon Labs • Lecturer, UC Berkeley MIDS • PhD Computer Science, University of Chicago
Software Engineering • Scientific-computing architect • 25 years building simulation capabilities at Ecolab
Semiconductors & Manufacturing • Senior leadership at Intel, KLA-Tencor, and AMD • 30+ years semiconductor manufacturing • MS Statistics, Texas A&M
NASA Goddard planetary scientist • Deputy PI, Cassini CIRS • BA Natural Sciences, Cambridge • MSc Astrophysics, Manchester
Space Science & Instrumentation • NASA Goddard, 30 years • Developed CIRS instrumentation for Cassini mission to Saturn • D.Phil Physics, Oxford
Founder & Managing Partner, TAP Sciences • Founded on the conviction that the structural gap between discovery and scaled application is a coordination problem before it is a capital problem • Has built networks of finance, operations, engineering, and science into coordinated capability at stages where conventional capital has no foothold
TAP engages with partners by referral. Whether an existing allocation framework fits or a new one is in development, the conversation starts the same way.